NICE rejects GSK's Revolade
This article was originally published in Scrip
Executive Summary
NICE, the National Institute for Health and Clinical Excellence, still has too many doubts about the long-term effectiveness of GlaxoSmithKline's oral thrombopoietin receptor agonist Revolade eltrombopag, called Promacta in the US, to recommend its use on the NHS for patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.